Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of CBD (Nantheia ATL5) in Healthy Volunteers
NCT05023070Phase 1Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jul 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cannabidiol in opioid use disorder (OUD), post-traumatic stress disorder (PTSD) and anxiety disorders (4 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoints: Safety and adverse effects, Peak plasma concentration at 24 hours and 1 more. Started Jul 2021; status: completed.
02
Drugs
cannabidiol
03
Conditions
opioid use disorder (OUD)post-traumatic stress disorder (PTSD)anxiety disorders
Beyond the preview
Go deeper on NCT05023070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05023070.